Trial | NCT01448733  Report issue

Title

Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris
A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the Treatment of Facial Acne Vulgaris.

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    20
The purpose of this study is to evaluate whether Cerave lotion followed by Acanya Gel in the morning in combination with Cerave lotion followed by Atralin gel in the evening is safe and effective for the treatment of acne vulgaris.
Study Started
Jul 31
2011
Primary Completion
Oct 31
2011
Anticipated
Study Completion
Oct 31
2011
Anticipated
Last Update
Oct 07
2011
Estimate

Drug Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening

Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening

  • Other names: Acanya Gel, Atralin Gel

Acanya Plus Atralin Experimental

A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.

Criteria 

Inclusion Criteria:

Males and females ≥ 12 years old.
Subjects must be in good general health as confirmed by medical history and physical examination.
Females of child-bearing potential must have a negative urine pregnancy test at the baseline visit and agree to be abstinent or use adequate birth control during the study (oral contraceptives, Norplant, Depo-Provera, or double barrier methods (e.g., condom and spermicide).
Clear diagnosis of facial acne vulgaris for at least 6 months.
Subject must have a static Physician's Global Assessment (PGA) of 2 (mild severity) or 3 (moderate severity).
Disease must be stable or slowly worsening for more than one week prior to entering the study.
Subjects or their guardians must be able to read, sign, and date the informed consent, and abide by study restrictions for its duration.

Exclusion Criteria:

Females who are pregnant, attempting to conceive, or breastfeeding.
Subjects with known hypersensitivity to any ingredients in the study drugs.
Subjects with overt signs of skin atrophy, telangiectasias or other skin findings that would affect efficacy evaluation.
Subjects with a current active skin malignancy or infection.
Subjects requiring the use of medications known to alter the course of acne vulgaris during the study treatment.
Subjects who have received systemic antibiotics within 2 weeks.
Subjects using systemic corticosteroids or immunosuppressants within 28 days of entering the study.
Subjects who have received any topical therapies for acne vulgaris within 7 days of entering the study.
Subjects taking birth control pills used solely for acne control.
Subjects who are currently participating in or, within the previous 28 days, have participated in another study for the treatment of acne vulgaris.
Subjects with clinical conditions that may post a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.
Subjects who have Crohn's disease, colitis, or if subjects ever developed colitis or severe diarrhea with past antibiotic use.
No Results Posted